Sign up Australia
Proactive Investors - Run By Investors For Investors

Anteo Diagnostics, IMRA America sign product development agreement

Both companies have signed a funded agreement to develop novel products for the in-vitro diagnostics industry. The initial focus will be on validating the proof of concept product built during the feasibility study.
Anteo Diagnostics, IMRA America sign product development agreement

Mark Bouris chaired Anteo Diagnostics (ASX:ADO) and IMRA America have entered into a funded Product Development Agreement following the successful combined use of Anteo’s Mix&Go™ Activation Reagent with IMRA’s proprietary gold colloids.

Anteo’s patented technology is Mix&Go, a “molecular glue" used in life sciences, pathology tests and point-of-care diagnostics to help identify and detect diseases more reliably and earlier.

This resulted in the development of a proof of concept product that should find a ready market given its functionality and growth in the in-vitro diagnostics market.

In December 2014, Anteo announced that it would collaborate with IMRA to develop a Gold Particle Coupling Kit, using its Mix&Go technology specifically tailored to IMRA's i-colloid gold product range.

A feasibility study revealed the combination yielded high purity, high quality pre-activated gold particles that are ready-to-use and deliver a product and novel functions not available to the market today.

The partners will develop products for the fast growing in-vitro diagnostics industry under the funded Product Development Agreement.

IMRA America is a global leader in the research, development, manufacture, and application of ultrafast fiber lasers.

The partners will develop products for the in-vitro diagnostics industry under a funded Product Development Agreement.

The resultant products are expected to deliver improvements to the colloidal stability and functionality of gold particles, leading to cheaper, improved assays and more accurate results.

IMRA uses laser-based proprietary manufacturing methods and produces high purity colloidal gold and other noble metal nanoparticles free of surfactants and residual chemical reagents.

Anteo and IMRA America will work closely together during the coming 6 months with the clear objective of delivering products ready for sale. The initial focus will be on validating the proof of concept product built during the feasibility study.

Rachel de las Heras, Anteo’s head of commercialisation, commented:

“Our Mix&Go technology together with IMRA’s high quality gold particles and comprehensive understanding of metal chelation, have allowed a strong mutual relationship that is reflected in this next stage of our partnership.

“With the positive feasibility study results at hand, we are confident that together, we can develop novel and widely applicable products that will see the IMRA and Anteo partnership deliver a range of valuable solutions to the market.”

Dr. Makoto Yoshida, IMRA’s executive vice president research and development, added:

“We have had a fruitful first stage of collaboration with encouraging outcomes. We expect to push this relationship further and develop outstanding products contributing to the biomedical and other societies.”


Collaboration

Since December 2014, the two companies have completed a feasibility study that considered how best to combine their respective products to develop novel products to be sold within the in-vitro diagnostics industry.

Key outcomes from the study include:

- The successful combination of Anteo’s Mix&Go Activation Reagent with IMRA’s proprietary gold colloids;
- The combination yielded high purity, high quality pre-activated gold particles that are ready-to-use; and
- Clear demonstration that the planned product concept will deliver a number of novel functions not available to the market today, including, ease-of-use (single buffer, fast protein coupling) and shortened assay product development cycles for manufacturers.


Mix&Go

Mix&Go is the healthcare application for Anteo’s nanoglue technology.

It uses coordination chemistry (rather than covalent chemistry or passive binding) for gentle and secure multipoint binding of biomolecules to synthetic surfaces.

This offers ease of use, increased antibody functionality and decreased background interference.

In turn, helping to reduce assay development costs, improve medical devices and in-vitro diagnostics, leading to the earlier detection of disease.

This features greater sensitivity of tests, reducing costs to manufacture and supporting the earlier detection of disease.


Analysis

Anteo's business model aims to transform the way scientists work by providing new, powerful tools developed with its patented Mix&Go™ Activation Reagent that advances traditional assay development methods.

This will crucially reduce assay development costs, improve medical devices and in-vitro diagnostics - leading to the earlier detection of diseases.

The partnership with IMRA will focus on validating the proof of concept product, a Gold Particle Coupling Kit that was developed during the feasibility study.

This collaboration should deliver a range of valuable solutions and products for the in-vitro diagnostics market, which could in time deliver cash flows.

Chief among the advantages of the combined product is the resultant products are expected to deliver improvements to the colloidal stability and functionality of gold particles.

In turn, this will lead to cheaper, improved assays and more accurate results.

The global in-vitro diagnostics market is growing strongly, double the rate of the global pharmaceutical industry.

Success in providing cost saving companion diagnostics tests and personalised medicine is tipped to see market revenue of $47.27 billion in revenue in 2013 and $62.63 billion estimated revenue by 2017 ($15 billion accessible).

The collaborative agreement provides significant promise for Anteo in 2015/16. Its focus on applications for its Nanoglue in the IVD and LS markets has just taken a quantum step forward.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.



Register here to be notified of future ADO Company articles
View full ADO profile View Profile

Anteo Diagnostics Timeline

Article
September 09 2016

Related Articles

picture of Paris
April 05 2017
Data from the European head and neck trial with lead product NBTXR3 will be presented at the ASCO meeting in June
Knee surgery
February 02 2017
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.
picture of drug research
June 05 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use